Prosensa Wins Scrip ‘Biotech Company of the Year’ 2014 Award

Leiden, The Netherlands, Dec. 8, 2014 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ: RNA), the bio­phar­ma­ceu­ti­cal com­pa­ny focus­ing on RNA-mod­u­lat­ing ther­a­peu­tics for rare dis­eases with a high unmet med­ical need, is delight­ed to have won the Scrip ‘Biotech Company of the Year’ Award for 2014, announced last week in London, UK.
The pres­ti­gious Scrip Awards pro­vide an oppor­tu­ni­ty to acknowl­edge and applaud the high­est achiev­ers across the biotech­nol­o­gy and phar­ma­ceu­ti­cal indus­try, rec­og­niz­ing both cor­po­rate and indi­vid­ual accom­plish­ments. The award for ‘Biotech Company of the Year’ is giv­en to the com­pa­ny which has demon­strat­ed the great­est achieve­ments for the year.
Hans Schikan, CEO of Prosensa, said, “Winning Scrip’s ‘Biotech Company of the Year’ Award is a great hon­or and a tes­ta­ment to the ded­i­ca­tion and hard work of the Prosensa team. Our dri­ve to suc­ceed is fueled by patients and their fam­i­lies, who con­tin­ue to inspire us to make inno­v­a­tive ther­a­pies avail­able as quick­ly and effi­cient­ly as pos­si­ble.”
The oth­er five final­ists were: Ablynx; Horizon Discovery; Isis Pharmaceuticals; Mesoblast; and Silence Therapeutics.

Leave a Reply

Your email address will not be published. Required fields are marked *